ERBB2 and gastric cancer: As far as we are aware, three randomized phase II trials have prospectively compared SP and XP for HER2-negative unresectable advanced or recurrent gastric cancer in Japan: the HERBIS-2 [10] and HERBIS-4A [11] trials performed by the Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG) and the XParTS II trial [12] conducted by the Epidemiological and Clinical Research Information Network (ECRIN).